Summary of Biopharmaceutic Study Reports — GLPI-103
| Field | Value |
|---|---|
| Document ID | CLINPHARM-001 |
| Version | 1.0 |
| Status | Final |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| CTD location | Module 5.3.1 — Reports of Biopharmaceutic Studies |
| Standard(s) | ICH M9 (biopharmaceutics classification / BE), M13; FDA/EMA bioavailability & food-effect guidance |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No dedicated biopharmaceutic dataset is simulated. Values are illustrative and consistent with a permeation-enhancer oral peptide and with IB-001, M2.7.1, and REF-002. This document stands in for the individual bioavailability, bioequivalence, and food-effect study reports (5.3.1.x) that a real submission would file in full.
Change History
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-07-05 | Clinical Pharmacology / Pharmaceutics | Initial submission-grade summary of biopharmaceutic studies (BA, relative BA/BE, food effect, IV↔oral bridging) |
Abbreviations
BA bioavailability · BE bioequivalence · CI confidence interval · F absolute bioavailability · GMR geometric mean ratio · IR immediate release · PE permeation enhancer · SNAC-type sodium N-[8-(2-hydroxybenzoyl)amino]caprylate-type absorption enhancer.
1. Overview and Formulations
GLPI-103 is developed in two clinical dosage forms whose biopharmaceutics differ fundamentally:
- Intravenous solution (once weekly): a sterile aqueous solution; bioavailability is complete (F = 1.0) by definition and serves as the reference for absolute oral bioavailability.
- Oral immediate-release tablet (once daily): the peptide is co-formulated with a permeation enhancer (SNAC-type) that transiently increases gastric epithelial permeability, enabling absorption of an otherwise non-permeant, protease-labile peptide. Absorption is highly dependent on local gastric conditions (fasting state, water volume, dosing-to-meal interval), a defining biopharmaceutic feature shared with marketed oral peptides.
The relationship between the two forms, and the conditions required for reproducible oral exposure, are the subject of the studies summarized below.
2. Absolute and Relative Bioavailability [MOCK]
| Study | Design | Result | Interpretation |
|---|---|---|---|
| Absolute BA | oral tablet vs IV reference, crossover | F ≈ 1–2% | Low but reproducible absolute BA typical of PE-enabled oral peptides; the clinical oral dose (2→8 mg) is set accordingly relative to the IV dose (1→4 mg) |
| Relative BA (tablet strengths) | 4 mg vs 2×2 mg, crossover | GMR within 0.80–1.25 | Dose-strength proportionality supports the marketed strengths |
| IV↔oral exposure bridging | popPK-informed | overlapping steady-state exposure ranges | Supports the two-formulation Phase 3 design and the exposure–response read across arms (CLINPHARM-002 §3) |
3. Food and Dosing-Condition Effect [MOCK]
The oral formulation is critically sensitive to administration conditions, consistent with the PE mechanism.
| Condition | Effect on oral exposure (AUC/Cmax) vs fasted reference | Recommendation |
|---|---|---|
| High-fat meal (fed) | markedly reduced (e.g., AUC ↓ ~60–70%) | Take on an empty stomach |
| Water volume (½ vs full glass) | reduced with larger volume | Take with a small sip of water (≤120 mL) |
| Post-dose fasting interval (0 vs 30 min) | reduced with shorter interval | Wait ≥30 minutes before eating/drinking or other oral medicines |
These conditions were carried into the protocol dosing instructions, the Pharmacy/IMP Manual (TMF-PHARM), and the labeling. Adherence to the fasting/administration conditions is a key determinant of oral efficacy and is reinforced in subject instructions and the ICF (TMF-ICF).
4. Bioequivalence / Bridging Across the Program [MOCK]
No formulation change of consequence occurred between the Phase 2 and Phase 3 oral tablet; the commercial IR tablet is qualitatively and quantitatively equivalent to the Phase 3 clinical tablet, so no in-vivo bioequivalence bridge was required. In-vitro dissolution and disintegration comparability data (Module 3.2.P.2) support the absence of a bridging gap. Where a future strength or process change occurs, a BE bridge under ICH M13 would be filed at 5.3.1.2.
5. In-Vitro / In-Vivo Considerations
Because absorption is permeability- rather than dissolution-limited for this PE-enabled peptide, a conventional IVIVC (in-vitro/in-vivo correlation) is not established; dissolution is used as a quality control and comparability tool (Module 3.2.P.5) rather than as a surrogate for bioavailability. This limitation is stated transparently and is characteristic of the oral-peptide class.
6. Conclusions
The IV form is fully bioavailable and serves as the exposure reference; the oral IR tablet achieves low (~1–2%) but reproducible absolute bioavailability via a permeation enhancer, with strong food and administration-condition dependence that is managed by explicit fasting/water/dosing-interval instructions. Dose-strength proportionality supports the marketed strengths, and no in-vivo bioequivalence bridge is required for the Phase 2→3→commercial oral tablet. These biopharmaceutic properties are integrated in Module 2.7.1 and underlie the two-formulation clinical strategy.
7. References
IB-001 §3, §5.1; M2.7.1; M3-P (drug product); CLINPHARM-002 (human PK); REF-002; TMF-PHARM; ICH M9, M13.